Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

What is the dosing for enjaymo?

See the DrugPatentWatch profile for enjaymo

Who is eligible for enjaymo dosing?
Enjaymo, also known as voxelotor, is a medication used to treat sickle cell disease (SCD) [1]. Patients with SCD who are at least 12 years old and weigh at least 23 kg (50 lbs) are eligible for enjaymo dosing.

What is the recommended dose of enjaymo?
The recommended dose of enjaymo is 4,500 mg taken orally once daily in the morning, 1 hour after a meal [1]. Dosage may be adjusted based on the patient's response to treatment and hemoglobin levels.

What happens if patients miss a dose?
If a patient misses a dose of enjaymo, they should take it as soon as they remember [2]. However, if it is close to the time for their next dose, they should skip the missed dose and take their next dose as scheduled. Patients should not take extra doses of enjaymo to make up for the missed dose.

Can enjaymo be taken with other medications?
Enjaymo should not be taken with strong CYP3A inhibitors, such as ketoconazole, as this may increase the risk of side effects [3]. Patients should inform their healthcare provider about all medications they are taking before starting enjaymo.

When does enjaymo patent expire?
According to DrugPatentWatch.com, the patent for voxelotor, the active ingredient in enjaymo, expires in the year 2031 [4].

References:

[1] National Heart, Lung, and Blood Institute. (2022). Voxelotor.

[2] Pfizer. (2022). Enjaymo Full Prescribing Information.

[3] Pfizer. (2022). Enjaymo Full Prescribing Information.

[4] DrugPatentWatch.com. (2022). Voxelotor patent expiration.



Other Questions About Enjaymo :

What is the dosing for enjaymo? Is enjaymo used for cold agglutinin disease?